Market Overview

UPDATE: Goldman Sachs Downgrades Allergan on Removal from America's Buy List

Share:
Related AGN
Top Takeaways From BMO's Specialty Pharma Day
Leerink Downgrades Kythera, Says Allergan Deal Likely To Close At $75 Mark
Allergan Is Buying Its Way To Growth (Investor's Business Daily)

In a report published on Friday, Goldman Sachs analyst Jami Rubin Downgraded Allergan (NYSE: AGN) from Buy to Neutral and maintained a $110 price target on the company.

In the report, Goldman Sachs stated, "We downgrade AGN from Buy to Neutral, within our Attractive coverage view; our estimates and 12-month price target of $110 are unchanged. We now see greater upside to FRX (Buy) with a $50, 12-month target, on the potential for significant restructuring/strategic alternatives and pending new management changes later this year. While AGN's base business remains solid (we forecast EPS growth of 15% over the next several years) driven by strong sales of Botox and the ophthalmic businesses, we see few near term catalysts that are likely to lead to upside EPS revisions or P/E expansion. Since adding to Buy list (4/19/10), AGN is +52% vs. S&P +33%."

Allergan closed on Thursday at $96.24.

Latest Ratings for AGN

DateFirmActionFromTo
Jun 2015BMO CapitalMaintainsOutperform
Dec 2014Goldman SachsDowngradesBuyHold
Dec 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Jami RubinAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters